Dorzolamide

DRUG6 trials

Sponsors

Region Vaesterbotten, Beacon Therapeutics (USA) Inc., University of Nebraska, University of Aarhus, University of Miami

Conditions

Diabetic RetinopathyDrug Effect (Glaucoma Drugs)GlaucomaX-linked retinitis pigmentosa (XLRP)open-angle and PEX glaucoma

Phase 2

Circadian Rhythms of Aqueous Humor Dynamics in Humans

CompletedNCT00572936

University of NebraskaGlaucoma

Start: 2006-03-13End: 2009-11-01Updated: 2023-10-24

Phase 3

Stop Retinal Ganglion Cell Dysfunction Study

TerminatedNCT02390284

University of MiamiGlaucoma

Start: 2015-09-30End: 2024-10-04Updated: 2025-08-26

A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa

WithdrawnCTIS2024-511181-36-00

Beacon Therapeutics (USA) Inc.X-linked retinitis pigmentosa (XLRP)

Target: 5Updated: 2024-09-17

Phase 4

Glaucoma Intensity Treatment Study – Intensive non-invasive glaucoma treatment vs conventional stepwise treatment – a prospective, randomized phase IV study of disease progression in glaucoma

Active, not recruitingCTIS2023-510041-16-00

Region VaesterbottenGlaucoma, open-angle and PEX glaucoma

Start: 2013-04-22Target: 240Updated: 2024-05-16

Unknown Phase

Pharmacological Intervention in Diabetic Retinopathy

CompletedNCT00619034

University of AarhusDiabetic Retinopathy

Start: 2007-09-30End: 2010-12-31Updated: 2010-12-29

Pupillary Response After Glaucoma Medication

CompletedNCT02522039

Glostrup University Hospital, CopenhagenDrug Effect (Glaucoma Drugs)

Start: 2014-05-31End: 2014-11-30Updated: 2015-08-13